Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
Abstract Individuals with chronic kidney disease are at an increased risk for cardiovascular disease. This risk may partially be explained by a chronic inflammatory state in these patients, reflected by increased arterial wall and cellular inflammation. Statin treatment decreases cardiovascular risk...
Guardado en:
Autores principales: | Renate M. Hoogeveen, Simone L. Verweij, Yannick Kaiser, Jeffrey Kroon, Hein J. Verberne, Liffert Vogt, Sophie J. Bernelot Moens, Erik S. G. Stroes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5c18abc477fa4ebbbdfb11d89e5dbb97 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EFFICACY OF ATORVASTATIN IN REDUCING PROTEINURIA IN PATIENTS OF CHRONIC KIDNEY DISEASE
por: Rizwan Azam, et al.
Publicado: (2019) -
Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Sejung Hwang, et al.
Publicado: (2021) -
Atorvastatin does not ameliorate nephrogenic diabetes insipidus induced by lithium or potassium depletion in mice
por: Maria L. Thomsen, et al.
Publicado: (2021) -
Nearby contours abolish the binocular advantage
por: Maria Lev, et al.
Publicado: (2021) -
Act Abolishing Slavery in the District of Columbia
Publicado: (2017)